Lymphadenopathy/pathology , Photosensitivity Disorders/pathology , Steroids/therapeutic use , Adolescent , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/virology , Hair , Humans , Male , Photosensitivity Disorders/diagnosis , Photosensitivity Disorders/drug therapy , SARS-CoV-2/genetics , Seasons , Steroids/administration & dosage , Treatment Outcome
Dermatitis, Seborrheic/diagnosis , Emollients/therapeutic use , Genital Neoplasms, Female , Gynecological Examination , Lichen Planus/diagnosis , Pruritus Vulvae , Psoriasis/diagnosis , Symptom Assessment , Biopsy/methods , Dermatitis, Contact/complications , Dermatitis, Contact/diagnosis , Diagnosis, Differential , Female , Genital Neoplasms, Female/diagnosis , Genital Neoplasms, Female/pathology , Gynecological Examination/methods , Gynecological Examination/psychology , Humans , Patient Care Management/methods , Pruritus Vulvae/diagnosis , Pruritus Vulvae/physiopathology , Pruritus Vulvae/psychology , Sexual Health , Symptom Assessment/methods , Symptom Assessment/psychology
An 8-year-old boy presented with eczematous skin lesions, recurrent otitis media and unexplained pyrexias. X-linked agammaglobulinaemia was diagnosed and treatment commenced with intravenous immunoglobulin replacement therapy. X-linked agammaglobulinaemia (XLA) is a primary immunodeficiency syndrome associated with a deficiency of B lymphocytes, caused by a defect in the expression of Bruton's tyrosine kinase. It affects only boys and usually presents before the age of 2 years with recurrent bacterial sinopulmonary infections. IgG levels are usually <2 g/L (normal range 5.4-16.1) and IgM and IgA are usually undetectable. The commonest cutaneous features of XLA are pyogenic skin infections; however, eczema can occur with increased frequency. We report a child who presented with multiple discrete eczematous lesions who subsequently developed eczematous exacerbations several days after administration of intravenous immunoglobulin (IVIg) replacement therapy.
Agammaglobulinemia , Genetic Diseases, X-Linked , Agammaglobulinemia/diagnosis , Agammaglobulinemia/drug therapy , Agammaglobulinemia/immunology , Anemia/complications , Anemia/therapy , B-Lymphocytes/immunology , Child , Dose-Response Relationship, Immunologic , Eczema/complications , Eczema/drug therapy , Genetic Diseases, X-Linked/diagnosis , Genetic Diseases, X-Linked/drug therapy , Genetic Diseases, X-Linked/immunology , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/adverse effects , Immunologic Factors/administration & dosage , Immunologic Factors/adverse effects , Male , Sex Factors , Treatment Outcome
Antitrust Laws , Criminal Law , Health Facilities/legislation & jurisprudence , Health Personnel/legislation & jurisprudence , Catchment Area, Health/legislation & jurisprudence , Dentists/legislation & jurisprudence , Hospital Charges/legislation & jurisprudence , Physicians/legislation & jurisprudence , Preferred Provider Organizations/legislation & jurisprudence , Rate Setting and Review/legislation & jurisprudence , United States , United States Federal Trade Commission
Acetylcysteine/pharmacology , Carcinoma 256, Walker/drug therapy , Cyclophosphamide/toxicity , Animals , Body Weight/drug effects , Cyclophosphamide/therapeutic use , Cystitis/chemically induced , Cystitis/prevention & control , Drug Administration Schedule , Drug Interactions , Male , Neoplasm Transplantation , Rats
Adenocarcinoma/drug therapy , Carcinoma, Small Cell/drug therapy , Carcinoma, Squamous Cell/drug therapy , Cyclophosphamide/analogs & derivatives , Ifosfamide/administration & dosage , Lung Neoplasms/drug therapy , Actuarial Analysis , Adult , Aged , Clinical Trials as Topic , Drug Administration Schedule , Female , Hematuria/chemically induced , Humans , Ifosfamide/adverse effects , Male , Middle Aged
Cyclophosphamide/analogs & derivatives , Ifosfamide/toxicity , Lung Neoplasms/drug therapy , Alopecia/chemically induced , Brain/drug effects , Drug Administration Schedule , Drug Evaluation , Hematuria/chemically induced , Humans , Ifosfamide/administration & dosage , Leukopenia/chemically induced , Nausea/chemically induced , Thrombocytopenia/chemically induced , United States , Vomiting/chemically induced
Antihypertensive Agents/pharmacology , Antihypertensive Agents/classification , Benzothiadiazines/therapeutic use , Emergencies/drug therapy , Guanethidine/therapeutic use , Humans , Hydralazine/therapeutic use , Hypertension/complications , Methyldopa/therapeutic use , Pargyline/therapeutic use , Pentolinium Tartrate/therapeutic use , Reserpine/therapeutic use